U.S. Pharma Stock News

Marsh, a business of Marsh & McLennan Companies, has entered a multi year global partnership with Formula 1. Marsh becomes Formula 1's first Official Risk Partner and Insurance Brokering Partner under this agreement. The partnership positions Marsh & McLennan (NYSE:MRSH) alongside one of the most widely followed global sports properties. For investors watching Marsh & McLennan at a current share price of $166.03, this Formula 1 tie up comes after a mixed share performance picture. The stock...

What Tri Pointe Homes’ Recent Returns Tell You Tri Pointe Homes (TPH) has drawn attention after a past 3 months total return of 32.4% and year to date return of 48.7%. These figures are prompting investors to reassess the stock’s recent momentum and underlying fundamentals. See our latest analysis for Tri Pointe Homes. Tri Pointe Homes’ recent share price return over 90 days of 32.4% and year to date share price return of 48.7%, alongside a 5 year total shareholder return of 93.37%, points to...

If you are wondering whether J. M. Smucker at around US$99 a share looks cheap, expensive, or somewhere in between, the starting point is understanding how its current price lines up against different measures of value. The stock is trading near US$99.44, with recent returns of 1.4% over 7 days, 5.6% over 30 days and 2.9% year to date. Over the last year the return sits at a 7.7% decline, and the 3 and 5 year returns are 29.9% and 14.3% declines respectively. These figures can affect how...

CME Group (NasdaqGS:CME) introduced the U.S. dollar RepoFunds Rate (RFR USD) this week as a new overnight repo market benchmark. The company also listed Avalanche (AVAX) and Sui (SUI) cryptocurrency futures, expanding its regulated crypto derivatives suite. These launches extend CME Group's reach in both fixed income market infrastructure and institutional crypto trading. CME Group, known for its global derivatives exchanges, is leaning further into rate benchmarks and digital assets as...

Willis Towers Watson (NasdaqGS:WTW) has completed its acquisition of Cushon, taking its UK defined contribution workplace pensions master trust assets to over £30b. The company has also launched an academic partnership with Cornell University focused on research into correlated catastrophic events. These moves expand WTW's UK pension offerings and deepen its catastrophe risk modeling capabilities. For investors watching NasdaqGS:WTW, this combination of pension consolidation and academic...

GigaCloud Technology (GCT) has kicked off Q1 2026 with total revenue of US$359.5 million and basic EPS of US$1.04, alongside trailing twelve month revenue of about US$1.38 billion and basic EPS of US$3.97. Over the past year, the company has seen quarterly revenue move from US$271.9 million in Q1 2025 to US$359.5 million in Q1 2026, with basic EPS over the same quarters shifting from US$0.68 to US$1.04. This sets the stage for investors to focus on how these earnings tie into GigaCloud...

If you are wondering whether FormFactor's recent run makes the stock look expensive or still interesting, you are not alone. That is exactly what this valuation-focused breakdown will unpack. The stock last closed at US$144.68, with returns of 6.4% over 7 days, 37.6% over 30 days, 144.4% year to date, 382.7% over 1 year and 404.3% over 3 years, compared with 335.9% over 5 years. These moves sit against a backdrop of ongoing investor interest in semiconductor-related businesses and...

Over the last 7 days, the United States market has risen by 3.2%, contributing to a remarkable 31% increase over the past year, with earnings projected to grow at an annual rate of 16%. In such a thriving market environment, identifying stocks that are estimated to be trading below their intrinsic value can present unique opportunities for investors seeking potential growth and value.

The United States market has experienced a robust performance, climbing 3.2% in the last week and rising by 31% over the past year, with earnings projected to grow by 16% annually in the coming years. In this thriving environment, growth companies with high insider ownership are particularly noteworthy as they often signal strong confidence from those closest to the business, aligning their interests with shareholders and potentially enhancing long-term value creation.

The United States market has shown robust growth, climbing 3.2% in the last week and up 31% over the past year, with earnings expected to grow annually by 16%. In this context of strong market performance, identifying stocks with solid financial foundations is crucial for investors looking to capitalize on potential gains. While the term "penny stocks" might seem outdated, these often-overlooked smaller or newer companies can offer unique opportunities for growth when supported by strong...

Over the last 7 days, the United States market has risen by 3.2%, and in the past year, it has climbed an impressive 31%, with earnings forecasted to grow by 16% annually. In such a dynamic environment, identifying promising stocks that combine solid fundamentals with growth potential can be key to uncovering hidden gems in the market.

The United States market has shown robust performance recently, with a 3.2% increase over the last week and a remarkable 31% rise over the past year, alongside an optimistic forecast of 16% annual earnings growth. In such an environment, dividend stocks that offer consistent payouts and potential for capital appreciation can be appealing options for investors seeking to balance income with growth opportunities.

Investors may be wondering whether Federal National Mortgage Association, at around US$8 a share, still offers value or whether most of the easy money has already been made. The stock has seen mixed returns, with a 2.2% pullback over the last 7 days, a 25.6% gain over 30 days, a 27.3% decline year to date and a 19.2% gain over the past year, alongside a very large return over three years and a near 3x return over five years. Recent price moves sit against a backdrop of ongoing interest in...

Lattice Semiconductor (NasdaqGS:LSCC) agreed to acquire AMI for US$1.65b. The deal is structured as a transformative move into AI, server management, and cloud infrastructure. The transaction is expected to be immediately accretive to gross margins, free cash flow, and non GAAP earnings, subject to regulatory approval. Lattice Semiconductor focuses on low power programmable logic devices that sit inside a wide range of electronics, from industrial systems to data center hardware. By adding...

Kratos Defense & Security Solutions (KTOS) opened 2026 with Q1 revenue of US$371 million and basic EPS of US$0.07, setting the tone for how its recent earnings momentum is feeding through to the bottom line. The company has seen quarterly revenue move from US$302.6 million and EPS of US$0.03 in Q1 2025 to US$371 million and EPS of US$0.07 in Q1 2026. Trailing twelve month EPS sits at US$0.17 on US$1.4b of revenue, giving investors a clearer read on how margins are tracking as the business...

Investors may be wondering whether Wingstop at around US$134.88 is starting to look interesting again, or if the stock’s valuation still feels out of step with its fundamentals. The share price has seen sharp moves recently, with a 17.8% decline over the last 7 days, an 18.8% decline over the last 30 days, and a 47.5% decline year to date. This will change how some investors think about both upside potential and risk. Recent coverage has focused on Wingstop’s position in the consumer...

Angi earnings shift draws investor focus Angi (ANGI) is in the spotlight after reporting first quarter 2026 results that showed sales of US$238.15 million, lower than the prior year, and a move from net income to a net loss. See our latest analysis for Angi. The earnings release and move to a quarterly net loss have coincided with a sharp reset in sentiment. Angi’s share price is at US$5.24 after a 90 day share price return of negative 55.78% and a 1 year total shareholder return of negative...

If you are wondering whether Ubiquiti at around US$926.69 is priced for perfection or still offers value, this article walks through what the current market price might be indicating. The stock has been volatile recently, with an 8.4% decline over the past week, a 10.7% return over 30 days, 63.6% year to date, 163.8% over 1 year, 435.7% over 3 years and 261.7% over 5 years. Recent attention on Ubiquiti has focused on its long term share price performance and what this means for current...

Why Azenta’s latest quarter is drawing attention Azenta (AZTA) has come under pressure after its second quarter report, which combined a US$149,083,000 goodwill and intangible asset impairment with a wider net loss, prompting investors to reassess the stock. See our latest analysis for Azenta. The earnings report and US$149.1m impairment have clearly shifted sentiment, with the 7 day share price return of negative 24.42% feeding into a year to date share price return of negative 44.38% and a...

In early May 2026, Harley-Davidson reported first-quarter net income of about US$24.77 million, sharply lower than a year earlier, as tariffs and higher costs compressed margins even while revenue of roughly US$1.17 billion exceeded analyst expectations and retail motorcycle sales rose, especially in North America. At the same time, management launched its "Back to the Bricks" turnaround plan, aiming to boost profitability through more affordable, rider-focused models, tighter dealer...

Unsurprisingly, Ambitions Enterprise Management Co. L.L.C's ( NASDAQ:AHMA ) stock price was strong on the back of its...

Bitdeer Technologies Group's ( NASDAQ:BTDR ) stock was strong after they recently reported robust earnings. However...

For investors wondering whether Bristol-Myers Squibb at around US$56.25 is offering value or risk at this point, this article breaks down what the current price might be indicating about the stock. The share price has had a mixed run, with a 7.2% loss over the last week and a 2.5% loss over the last month, but it is still up 5.2% year to date and 26.0% over the past year. Recent headlines around Bristol-Myers Squibb have focused on its position within the broader pharmaceuticals space and on...

Iovance Biotherapeutics (IOVA) opened Q1 2026 with revenue of US$71.4 million and a basic EPS loss of US$0.19, alongside net income excluding extra items at a loss of US$79.0 million. Over recent quarters, the company has seen revenue move from US$49.3 million in Q1 2025 to US$71.4 million in Q1 2026. Quarterly basic EPS losses ranged between US$0.18 and US$0.36 across that period, illustrating that top line scale is increasing while spending remains high and margins stay under pressure. See...